Notch-stimulated signaling cascade results in transcriptional regulation of genes involved in cell fate decision, apoptosis and proliferation and has been implicated in various malignancies. Here, we investigated the impact of MRK003, an inhibitor of this pathway, on myeloma and lymphoma cells. We first studied the expression patterns of notch receptors and ligands on multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL) cell lines. Next, we used a c-secretase inhibitor, MRK003 to test the importance of notch-stimulated pathways in MM and NHL disease biology. We observed expression of notch receptors and ligands on MM and NHL cell lines. MRK003 treatment induced caspase-dependent apoptosis and inhibited proliferation of MM and NHL cell lines and patient cells. Examination of signaling events after treatment showed time-dependent decrease in levels of the notch intracellular domain, Hes1 and c-Myc. MRK003 downregulated cyclin D1, Bcl-Xl and Xiap levels in NHL cells and p21, Bcl-2 and Bcl-Xl in MM cells. In addition, MRK003 caused an upregulation of pAkt, indicating crosstalk with the PI3K/Akt pathway. We evaluated MRK003 in combination with Akt1/2 kinase inhibitor and observed synergy in killing MM and NHL cell lines examined.
Introduction
Multiple myeloma (MM) is a malignancy of plasma cells and remains incurable despite recent advances in therapy. NonHodgkin's lymphoma (NHL) is the most common cancer of the lymphatic system and represents a heterogeneous group of disease. Depending on the type of NHL, response to treatment could vary greatly from being curable to being resistant to available therapies. Novel therapies based on the disease biology are required to improve patient outcome in both these cancers.
Notch proteins are high molecular-weight transmembrane proteins that are implicated in a broad spectrum of cellular events, including embryonic development, cell fate determination, differentiation, proliferation and apoptosis. 1 Notch proteins are expressed on cell membranes as a heterodimer, 2 and their activation requires the interaction of notch ligands expressed on adjacent cells. 3 Two major families of notch ligands have been reported, namely Delta like (Dll) and Jagged. Upon ligand binding, notch undergoes sequential cleavage first at the extracellular domain by a metalloprotease. 4, 5 This cleavage is followed by a cleavage at the transmembrane domain by the g-secretase complex. 6, 7 This releases the notch intracellular domain (NICD) to the cytoplasm, which then enters the nucleus and promotes transcription of several genes, including Hes1, c-Myc, p21, NF-kB and cyclin D1. [8] [9] [10] [11] [12] Dysregulated notch signaling has been reported in several solid tumors. [13] [14] [15] In hematological malignancies, chromosomal alterations and activating mutations of notch 1 have been found to occur in patients with T-cell acute lymphoblastic leukemias, with activating mutations seen in 450% of patients. [16] [17] [18] [19] A recent study has identified activating mutations in the PEST domain of the notch 2 protein in diffuse large B-cell lymphoma. 20 However, the importance of the notch pathway in tumorigenesis is not fully understood. Few reports have demonstrated activated notch to induce apoptosis and protect cells from drug-induced apoptosis in B-cell malignancies. 21, 22 However, few others have reported the notch pathway to be oncogenic, and inhibiting the notch-stimulated pathway using g-secretase inhibitors (GSIs) have demonstrated growth inhibition and apoptosis of MM and Hodgkin's lymphoma cell lines. [23] [24] [25] In addition, the notch pathway has been shown to be upregulated after myeloma cell interaction with bone marrow stromal cells (BMSCs). 21, 26 This upregulation leads to enhanced growth arrest and protection of myeloma cells from chemotherapy.
Here, we report pre-clinical activity of MRK003, a GSI, on MM and NHL cell lines and patient cells in vitro. Pre-clinical studies in T-cell acute lymphoblastic leukemia, breast cancer, lung cancer and pancreatic ductal adenocarcinoma using MRK003 have reported potent notch pathway inhibition and induction of apoptosis. [27] [28] [29] [30] We observed that MRK003 induced apoptosis and inhibited proliferation of MM and NHL cell lines. MRK003 led to downregulation of canonical pathway members in both MM and NHL cells. Our results also showed upregulation of pAkt after drug treatment. On the basis of our mechanistic studies, we tested MRK003 in combination with Akt1/2 kinase inhibitor (Akti) and observed synergy in killing MM and NHL cells.
Materials and methods

MM cell lines and NHL cell lines
Dexamethasone-sensitive (MM1.S) and dexamethasone-resistant (MM1.R) human MM cell lines, doxorubicin-resistant (DOX 40) and melphalan-resistant (LR5) RPMI 8226 human MM cell lines and sensitive RPMI 8226 cell line, OPM-2, NCI-H929 and U266 cell lines were used for the current study. Lymphoma cell lines used included Ramos (Burkitt's lymphoma), Dohh2 and Karpas 422 (follicular lymphoma) and Granta 519 (mantle cell lymphoma). All cell lines were cultured in RPMI 1640 media (Sigma Chemical, St Louis, MO, USA) that contained 10% fetal bovine serum, 2 mM L-glutamine (Gibco, Grand Island, NY, USA), 100 Units/ml penicillin and 100 mg/ml streptomycin.
Patient cells
Freshly obtained bone marrow aspirates from patients were collected with informed consent and processed to obtain myeloma cells or stromal cells as described previously. 31, 32 Lymphoma cells were harvested from tissue samples of lymphoma patients. Lymph nodes or spleen were forced through wire screens to suspend cells. All patient cells were cultured in RPMI 1640 media (Sigma Chemical) that contained 20% fetal bovine serum, 2 mM L-glutamine (Gibco), 100 Units/ml penicillin and 100 mg/ml streptomycin.
MRK003 and Akti
MRK003, a cyclic sulfamide GSI was synthesized and provided by Merck and Co. Inc. (Whitehouse Station, NJ, USA) under a Material Transfer Agreement. Stock solutions were prepared in dimethyl sulfoxide at a concentration of 100 mM, aliquoted and stored at À20 1C. Akti was purchased from Sigma-Aldrich Corp. (St Louis, MO, USA). Stock solutions were prepared in dimethyl sulfoxide at a concentration of 10 mM, aliquoted and stored at 4 1C. The drugs were subsequently diluted in RPMI 1640 medium at the desired concentration before use.
Reverse transcriptase-PCR
Total RNA was isolated from cell lines using an RNeasy kit as described by the manufacturer (Qiagen Inc., Valencia, CA, USA). In all, 100 ng of RNA was used in a one-step reversetranscriptase-PCR kit as described by the manufacturer (Qiagen Inc.). Primer sequences used were: notch 1: forward: CAGCTGC ACTTCATGTACGTG, reverse: GGCAGACACAGCCGCATGCA GC; notch 2: forward: CCACCAGGCACTCGGGGCCTA, reverse: GGAGTAATAAGGAGGCTGGCG; notch 3: forward: AAGCGG CTAAAGGTAGAGGAG, reverse: GCATCGGCTGTGACAGCT GTG; notch 4: forward: TGGGTATCTCTGCCAGTGTGC, reverse: CAGTGGCAGATGAAACCCAGG; Dll1: forward: GAGGGAGG CCTCGTGGA, reverse: AGACCCGAAGTGCCTTTGTA; Dll3: forward: CGGATGCACTCAACAACCT, reverse: GAAGATGGC AGGTAGCTCAA; Dll4: forward: GCATTGTTTACATTGCATC CTG, reverse: GCAAACCCCAGCAAGAGAC; Jagged 1: forward: CTATGATGAGGGGGATGCT, reverse: CGTCCATTCAGGCAC TGG; Jagged 2: forward: TGGGATGCCTGGCACA, reverse: CCGGCAGATGCAGGA. PCR amplified fragments were analyzed by electrophoresing using a 1% agarose gel.
Cell viability and proliferation assays
Myeloma and lymphoma cells were incubated with the indicated concentrations of MRK003 or Akti or the combination in a 96-well flat-bottomed culture tray for 48 h. After incubation, viability and proliferation were measured using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrasodium bromide) (Chemicon International Inc., Temecula, CA, USA) colorimetric assay and tritium uptake studies, respectively, as described previously. 33, 34 All experiments were performed in triplicate.
Apoptosis measurement
Apoptosis of MM and lymphoma cell lines was assayed as described before. 33, 34 In brief, control or drug-treated cells were subjected to two washes with the annexin-binding buffer. In all, 100 ml cells (10 7 cells per ml) were treated with 3 ml annexin V-fluorescein isothiocyanate (Caltag, Burlingame, CA, USA) for 15 min at room temperature. Cells were washed again with annexin-binding buffer and resuspended in 500 ml of annexinbinding buffer containing 5 ml of 1 mg/ml propidium iodide (Sigma Chemical). The samples were subsequently run on a Canto flow cytometer (BD Biosciences, San Jose, CA, USA). Experiments were repeated thrice. For patient cells, fresh bone marrow cells were subject to ACK lyse, washed, resuspended in RPMI/10% fetal bovine serum and plated in 24-well tissue culture plates for 48 h. Cultures were harvested, washed once in phosphate-buffered saline and resuspended in 1 ml phosphate-buffered saline/3% bovine serum albumin. In all, 100 ml of the cell suspension was stained with APO 2.7 phycoerythrin (PE) (Beckman Coulter, Miami, FL, USA) or isotype control PE for a minimum of 15 min. Cells were washed once with phosphate-buffered saline and resuspended in 1% paraformaldehyde and stored at 4 1C, in the dark, until run on the Canto flow cytometer (BD Biosciences).
Caspase assay
Levels of caspases 3, 8 and 9 were indirectly determined by the production of FL1 fluorescence by cleaved substrate using kits purchased from OncoImmunin (Gaithersburg, MD, USA). PhiPhiLux G1D2 (catalog no. A304R1G-3) was used for detection of caspase 3, whereas CaspaLux 8 L1D2 (catalog no. CPL8R1L-3) and CaspaLux 9 M1D2 (catalog no. CPL9R1M-3) were used for detection of caspases 8 and 9, respectively. Samples were run on a Canto flow cytometer (BD Biosciences). Experiments were repeated thrice.
Western blotting
The MM cell line RPMI 8226, NHL cell line DOHH2 and two freshly isolated CD138 þ cells from two MM patients were used for this experiment. Cells were harvested and lysed with RIPA buffer (50 mM HEPES (pH 7.4), 150 mM NaCl, 1% Triton X-100, 30 mM sodium pyrophosphate, 5 mM EDTA, 2 mM Na 3 VO 4 , 5 mM NaF, 1 mM phenylmethylsulfonyl fluoride and protease inhibitor cocktail). Protein lysate concentrations were measured using the bicinchoninic acid assay (Pierce, Rockford, IL, USA). Equal amounts of protein were loaded on Tris-glycine gels and transferred onto nitrocellulose membranes. Membranes were probed with NICD, c-Myc, cyclin D1, p21, p65, pAkt, Akt, pErk, Erk, Mcl1, Bcl2, Bcl-Xl, Xiap (Cell Signaling, Danvers, MA, USA), Hes1, p50, p52, RelB and c-Rel (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Blots were reprobed with antib-actin antibody (Cell Signaling) as a control. Experiments were repeated thrice.
Angiogenesis assay
We performed an in vitro angiogenesis assay to test the effects of MRK003 to inhibit angiogenesis as described earlier. 35 We cocultured human endothelial cells with human fibroblasts and myoblasts in a 24-well plate with media. After 2 weeks, endothelial cells because of their ability to proliferate and migrate form a network of spindles. Co-cultured endothelial cells were treated with one of the following: vascular endothelial growth factor (VEGF) (positive control) or suramin (negative control) or indicated doses of MRK003. In addition, a couple of wells were not subjected to any treatment (no treatment control).
Isobologram analysis
The interaction between MRK003 and Akti was analyzed using the CalcuSyn software program (Biosoft, Ferguson, MO, USA). This program is based on the Chou-Talalay method, which calculates a CI (combination index), and analysis is performed based on the following equation:
, where (D)1 and (D)2 are the doses of drug 1 and drug 2, respectively, that have x effect when used in combination, and (Dx)1 and (Dx)2 are the doses of drug 1 and drug 2, respectively, that have the same x effect when used alone. 36 A CI of 1.0 indicates an additive effect, whereas CI values below 1.0 indicate synergism.
Results
MM and NHL cells express notch receptors and ligands
We first examined the expression patterns of notch and their ligands on MM and NHL cells. We examined expression levels of all four notch isoforms (notch 1, 2, 3 and 4). We observed high levels of expression of notch 2 in all MM ( Figure 1a ) and NHL ( Figure 1b ) cell lines tested. Notch 1 was expressed in all MM cell lines except U266, with high levels of expression observed in MM1S and MM1R ( Figure 1a ). All lymphoma lines tested expressed notch 1 with high levels of expression in granta cells (Figure 1b ). RPMI 8226, MM1S and MM1R cells did not express notch 3, whereas U266 cells expressed high levels of notch 3 ( Figure 1a ). MM cell lines H929 and MM1S were observed to not express notch 4 ( Figure 1a ). The Burkitt lymphoma cell line Ramos was negative for notch 3 and notch 4 ( Figure 1b) .
We also examined expression levels of notch ligands Dll (Dll1, 3 and 4) and Jagged (Jagged 1 and 2). The MM cell line MM1R was found to not express Dll1, whereas all other cell lines expressed detectable levels. MM1R and U266 did not express Dll3, whereas H929 and LR5 did not express Dll4 ( Figure 1c ). All lymphoma cell lines examined expressed Dll1, 3 and 4 ( Figure 1d ). All MM and NHL cell lines examined were negative for Jagged 1 expression (data not shown). However, jagged 2 was expressed on all MM and NHL cell lines, except on the karpas cell line (Figures 1c and d) .
MRK003 induces cytotoxicity and inhibits proliferation in all MM and NHL cell lines
To understand the importance of the notch pathway in MM and NHL disease biology, we used MRK003, a GSI to inhibit this pathway. When cells were incubated with indicated concentrations of MRK003 for indicated time points, we observed druginduced cell death in all MM and NHL cell lines tested with IC50 values of 15-30 mM in MM cell lines and 15-25 mM in NHL cell lines (Figures 2a and b) . Granta 519 was resistant to MRK003 treatment at concentrations tested. We observed that MRK003 inhibited proliferation of both MM and NHL cells (Figures 2c and d ). MRK003 induced apoptosis at similar levels in all MM cell lines tested with MM1S cells being the most sensitive. However, MRK003 was able to more potently inhibit the proliferation of MM1S, MM1R, H929 and U266 cells at lower concentrations when compared with RPMI 8226, Dox40 and LR5 cells (Figures 2a and c) .
MRK003 overcomes protective effects of the microenvironment on MM and NHL cells
It is known that cellular and non-cellular components of the tumor microenvironment protect MM and NHL cells from the cytotoxic effects of many drugs. We examined the ability of MRK003 to inhibit proliferation of MM and NHL cells when cultured with components of the microenvironment. First, we cultured the MM cell line MM1S in the presence or absence of patient-derived BMSCs and incubated them with indicated concentrations of MRK003, which inhibited proliferation of MM1S cells at similar levels both in the presence or absence of BMSCs (Figure 2e ). We co-cultured MM1S or Dohh2 
MRK003 induces apoptosis in MM and NHL cell lines and patient cells in vitro
Next, we wanted to address whether MRK003-induced cytotoxicity is mediated through apoptotic cell death. For this, we incubated MM1S, RPMI 8226 or Dohh2 cells with indicated concentrations of MRK003 for 6, 24 or 48 h. We observed timedependent increase in cells undergoing apoptosis in all the cell lines studied (Figures 3a-c) . To better understand the mechanism of drug-induced apoptosis, we measured levels of activated caspases. We observed time-dependent increase in activated caspase levels (caspases 3, 8 and 9) in both MM1S and Dohh2 cells (Figures 3d and e) . This confirmed the involvement of caspases in MRK003-induced apoptosis, although additional mechanisms of cell death could be involved. We then studied whether MRK003 induced apoptotic cell death in MM and NHL patient-derived cells. For this, we incubated patient cells with indicated concentrations of the drug and measured cells undergoing apoptosis and observed varying degrees of dose-dependent increases in apoptotic cells in MM patients (Figure 3f ) and in NHL patients (Figure 3g ).
Canonical pathway members are downregulated by MRK003
We next examined the signaling events modulated by MRK003 in both MM and NHL cells that might be responsible for the increased apoptotic cell death observed. We observed that MRK003 treatment resulted in downregulation of the NICD and the transcription factor Hes1 with a more pronounced downregulation observed in the NHL cell line Dohh2 (Figure 4b ) than in the MM cell line RPMI 8226 (Figure 4a ). We also observed downregulation of other canonical pathway members, namely c-Myc and p21, with the downregulation being more pronounced in RPMI 8226 (Figure 4a ) than in Dohh2 (Figure 4b ). Cyclin D1, another canonical downstream target of notch was downregulated only in Dohh2 cells (Figure 4b ) and not in RPMI 8226 cells (Figure 4a ).
MRK003 modulates other signaling pathways and downregulates several anti-apoptotic proteins in MM and NHL cells
The PI3K (phosphoinositide 3-kinase)/Akt and Ras/Mek/Erk pathways are both important in MM and NHL disease biology. To understand whether MRK003 indirectly modulates these pathways, we examined the expression levels of important members of these pathways. MRK003 treatment resulted in decreased pErk expression in RPMI 8226 cells. However, phosphorylated extracellular signal-regulated kinase was upregulated after MRK003 treatment in Dohh2 cells indicating differential pathway regulation in MM and NHL cells (Figures 4c  and d) . pAkt was found to be slightly upregulated after MRK003 (Figures 4c and d) .
In addition, we also studied whether MRK003 treatment led to downregulation of important anti-apoptotic proteins. MRK003 did not decrease levels of Mcl1 in both RPMI 8226 and Dohh2 cells (Figures 4c and d) . However, MRK003 resulted in downregulation of Bcl2 and Bcl-Xl in RPMI 8226 cells (Figure 4c) . In Dohh2 cells, MRK003 caused downregulation of Bcl-Xl and Xiap (Figure 4d ).
MRK003 modulates the NF-kB pathway
Given that the notch-stimulated pathway activates the nuclear factor-kB (NF-kB) pathway, 11 we investigated whether MRK003
acts by inhibiting the NF-kB pathway. In RPMI 8226 cells, MRK003 did not change the expression levels of p65, p50, p52 and c-Rel (Figure 4e ). However, MRK003 induced the expression of RelB, which might indicate partial activation of the noncanonical NF-kB pathway (Figure 4e) . In Dohh2 cells, MRK003 led to downregulation of p65 with no change in the expression of other NF-kB proteins (Figure 4f ). 
MRK003 influences changes in both canonical and non-canonical pathway members in MM patient cells
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In patient 1, we observed that among the canonical pathway members, there was downregulation of only cyclin D1 and p21 (Figure 4g ). We were unable to detect expression levels of other canonical pathway proteins in patient 1. However, in patient 2, we observed downregulation of NICD, Hes1 and c-Myc with no change in p21 levels ( Figure 4h ). Next, we observed that in patient 1, MRK003 inhibited the NF-kB pathway as evidenced by the downregulation of p65, p50, p52 and RelB. This was accompanied by reduction in levels of anti-apoptotic proteins Bcl2, Bcl-Xl and Mcl1 (Figure 4g ). However, in patient 2, we did not observe any influence of MRK003 on the NF-kB pathway. However, we observed downregulation of Mcl1, Xiap and a slight downregulation of Bcl2 (Figure 4h ). Clearly, MRK003 elicits its effects through different mechanisms in different patient cells.
MRK003 inhibits angiogenesis in vitro
The expression of notch ligand Dll4 is known to be regulated by VEGF. 37, 38 Abolishing Dll4 expression leads to increase in non-productive vascularity and decrease in tumor growth. 38 Given that both MM and NHL cells express Dll4 (Figures 1c  and d ) and given that there is increased secretion of VEGF and other pro-angiogenic cytokines by the tumor cell and cells of the microenvironment, 39, 40 it remains likely that inhibiting Dll4 in particular or inhibiting the notch pathway might lead to decrease in angiogenesis. Our results show that MRK003 inhibits angiogenesis in vitro at concentrations much lower than apoptotic concentrations. MRK003 was not found to affect angiogenesis when used at concentrations p1 mM ( Figure 5 ). At 10 mM, a concentration lower than its apoptotic concentration, MRK003 inhibited angiogenesis significantly ( Figure 5 ). VEGF 
MRK003 synergizes with Akti in MM and NHL cells
As MRK003 treatment resulted in upregulation of pAkt, we hypothesized that MRK003 might synergize in killing MM and NHL cells when used in combination with an inhibitor of the PI3K/Akt pathway. To address this, we pre-treated both MM and NHL cells with indicated concentrations of Akti. Sixteen hours later, these cells were treated with MRK003 and incubated for an additional 32 h. Viability of cells after drug treatment was measured. We observed synergy when MRK003 was used in combination with Akti (Tables 1a and b )
Discussion
The notch pathway has been implicated in the pathogenesis and progression of different tumors. Expression of the receptors and the ligands has been reported in the different tumors studied. In this study, we first studied expression levels of notch receptors and their ligands on MM and NHL cell lines. Both MM and NHL cell lines were found to express more than one notch receptor and ligand and the expression was quite heterogeneous. Interestingly, none of the cell lines expressed Jagged1 in the current study in contrast to a previous report. 23 Next, we studied the pre-clinical activity of MRK003, a GSI as an anti-MM and anti-NHL agent in vitro. Our results clearly demonstrated induction of cytotoxicity and inhibition of proliferation in MM and NHL cell lines. The tumor microenvironment has an essential role in MM disease progression. 41 Both cellular and non-cellular components of the microenvironment have important roles in disease progression and resistance to chemotherapy. 41 Jagged 1 is abundantly expressed in BMSCs, and interaction of MM cells with BMSCs could further stimulate the notch pathway. 42 Hence, we co-cultured MM cells with MM patient-derived BMSCs and incubated them with MRK003.
MRK003 was able to overcome protective effects of BMSCs and inhibit proliferation of MM cells.
Notch receptors expressed as heterodimers on cell membrane undergoes sequential cleavage and gets converted to a shorter activated form of notch comprising the NICD. By western blots, we showed that Dohh2 and RPMI 8226 cells constitutively express NICD (Figures 4a and b) . MRK003 inhibited the expression of NICD confirming that the drug was able to inhibit notch activation in both NHL and MM cells.
The notch pathway regulates the expression of various proteins, few being tumorigenic and few others being tumor suppressors. Some of the canonical downstream members regulated by notch are Hes1, c-Myc, cyclin D1 and the tumor suppressor p21. We examined expression levels of these proteins after MRK003 treatment. In RPMI 8226 cells, c-Myc and p21 were significantly downregulated after MRK003 treatment (Figure 4a ). The downregulation of p21 might explain why MRK003 is less potent in inhibiting proliferation in RPMI 8226 and its drug-resistant variant cell lines Dox40 and LR5 when compared with the apoptotic effects induced by MRK003 In this experiment, we performed an in vitro angiogenesis assay to observe possible antiangiogenic capability of MRK003. Suramin was used as a negative control and VEGF as a positive control. MRK003 caused a decrease in tubule formation. There was no decrease in tubule formation when 1 mM of MRK003 was used. However, there was a significant and almost complete decrease in tubule formation at 10 mM, a concentration lower than the IC50 value of MRK003 on MM and NHL cells indicating the ability of MRK003 to inhibit angiogenesis. (Figure 4b ). p21 expression is known to be regulated by notch proteins. In small cell lung cancers, notch proteins activated p21 and caused growth arrest. 43 In MM, notch 1 has been found to upregulate p21 expression and induce growth arrest and provide resistance to drug-induced apoptosis. 21 Therefore, the ability of MRK003 to inhibit p21 might make MM cells sensitive to apoptosis induced by other drugs when used in combination. The lack of downregulation of p21 in Dohh2 cells might explain why NHL cells were found to be more sensitive to MRK003.
Examining other signaling pathways implicated in MM and NHL disease biology indicated upregulation of pAkt levels after drug treatment (Figures 4c and d) . Notch has been shown to positively regulate the mTOR (mammalian target of rapamycin) pathway with inhibition of notch leading to downregulation of proteins downstream of mTOR. 44 mTORC1 downregulation leads to a mTORC2-mediated feedback upregulation of pAkt. 45 This might explain why pAkt is upregulated after MRK003 treatment. Therefore, we examined the effects of using Akti in combination with MRK003 and observed marked synergy in killing both MM and NHL cells (Tables 1a and b) .
Notch1 was found to induce expression of several NF-kB proteins, namely p65, p50, RelB and c-Rel. 11 In another study, it was found that activated notch (NICD) activates transcription of the NF-kB2 (p100/p52) gene. 46 Activation of the NFKB pathway was found to be important for cell adhesion-mediated drug resistance in MM cells. 47 However, cell-bound Jagged 1 was unable to activate notch-mediated activation of NF-kB in the MM cell line H929. 21 To understand whether some of the apoptotic effects induced by MRK003 are due to inhibition of the NF-kB pathway, we examined changes in expression levels of NF-kB observed after MRK003 treatment. We observed that MRK003 did not inhibit p65, p50, p52 or c-Rel with a slight induction of RelB in the MM cell line RPMI 8226 (Figure 4e) . Induction of RelB might indicate activation of the non-canonical NF-kB pathway. In Dohh2 cells, MRK003 caused downregulation of p65 with no observable differences seen in any of the other NF-kB proteins (Figure 4f ). These results indicate that notch differentially regulates the NF-kB pathway in different tumor systems.
It is important to note that GSIs have multiple targets apart from notch and this could lead to non-specific effects in vivo. GI toxicity has been observed in mouse models treated with a GSI. 48 Therefore, combination therapies with sub-IC50 doses of GSI might be useful in a clinical setting. Taken together, our studies present pre-clinical evidence for MRK003 as an anti-MM and anti-NHL agent. Clinical trials of Akt inhibitors with notch pathway inhibitors are warranted.
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